Over the past two decades, research has identified extrasynaptic GABA A receptor
populations that enable neurons to sense the low ambient GABA concentrations present in …

Glutamatergic and cholinergic dysfunction are well‐attested features of Alzheimer's disease
(AD), progressing with other pathological indices of the disorder and exacerbating neuronal …

α5 subunit containing GABA type A receptors (GABAARs) have long been an enigmatic
receptor subtype of interest due to their specific brain distribution, unusual surface …

Gamma‐aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central
nervous system. GABA type A receptors (GABAAR s) are severely affected in Alzheimer's …

GABAA receptors are clustered at synaptic sites to achieve a high density of postsynaptic
receptors opposite the input axonal terminals. This allows for an efficient propagation of …

GABA A receptors in the CNS mediate both fast synaptic and tonic inhibition. Over the past
decade a phasic current with features intermediate between fast synaptic and tonic …

Cognitive enhancers (nootropics) are drugs to treat cognition deficits in patients suffering
from Alzheimer's disease, schizophrenia, stroke, attention deficit hyperactivity disorder, or …

Alzheimer's disease (AD) is the most common neurological disease, which is associated
with gradual memory loss and correlated with synaptic hyperactivity and abnormal …

Insulin signaling to the brain is important not only for metabolic homeostasis but also for
higher brain functions such as cognition. GABA (γ-aminobutyric acid) decreases neuronal …

In the mammalian central nervous system (CNS) GABA A receptors (GABA A Rs) mediate
neuronal inhibition and are important therapeutic targets. GABA A Rs are composed of 5 …